复星医药向专业投资者公开发行科技创新公司债券获中国证监会注册批复

Core Viewpoint - Fosun Pharma has received approval from the China Securities Regulatory Commission (CSRC) to publicly issue technology innovation corporate bonds with a total face value of up to RMB 6 billion [1] Group 1 - The approval allows Fosun Pharma to issue the bonds to professional investors within a validity period of 24 months from the date of approval [1] - The company plans to issue the bonds in phases based on funding needs and market conditions during the registration validity period [1] - Fosun Pharma will comply with relevant laws, regulations, and disclosure obligations as required by the approval and authorized by its shareholders [1]